Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma

Condition:   Hepatocellular Carcinoma Interventions:   Procedure: Surgical Resection;   Drug: Adjuvant Atezolizumab-Bevacizumab Therapy Sponsors:   National Cancer Centre, Singapore;   Singapore General Hospital;   National University Hospital, Singapore;   Changi General Hospital;   Sengkang General Hospital;   Tan Tock Seng Hospital;   Singapore Clinical Research Institute;   Genome Institute of Singapore;   I nstitute of Molecular and Cell Biology of Singapore;   Cancer Science Institute of Singapore;   Duke-NUS Graduate Medical School;   Singapore Phenome Centre;   Nanyang Technological University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials